Precision cancer medicine: Spatiotemporal genomes heterogeneity opens new therapeutic horizons

Global Congress on Tissue Engineering, Regenerative & Precision Medicine

December 1-2, 2016 | San Antonio, USA

Dimitris Roukos

Ioannina University, Greece

Posters & Accepted Abstracts: J Tissue Sci Eng

Abstract :

Background: Metastasis is the cause of death for millions of cancer patients annually worldwide. Spatiotemporal identification of resistant sub clones using breakthrough technological genome systems and methods can predict and prevent therapeutic resistance and metastatic relapse before it clinically occurs on the basis of genotype-phenotype map. Architecture of genome and nonlinear transcription: Clinical studies coupled with mathematical and experimental models, indicate that in some patients pre-existed large structural genome changes [copy number alterations (CNAs), chromosomal rearrangements] predict metastasis and death. But in most patients dynamic emergence of somatic mutations leading to intratumor heterogeneity results in metastasis as a late event or development of secondary resistance and metastatic relapse. Based on the dynamics of genomic clone�s evolution following Darwinian�s principles, innovative methods and next-generation sequencing (NGS) systems have been developed. Moreover, in the post-ENCODE era breakthrough approaches are being developed for understanding and disrupting transcriptional deregulated bio circuits with future nonlinear drugs. This lecture presents how using primary tumor multiregional NGS analysis, single-cell genome-NGS, circulating genomes sequencing as well as CRISPR-Cas system we could understand non coding genome functionality and comprehensive interpatient heterogeneity (IPH). This spatiotemporal IPH can not only predict therapeutic resistance and metastasis but also shape the discovery of novel both linear and nonlinear transcription drugs.

Biography :

Email: droukos@uoi.gr